Market accessOfficial

SÚKL publishes Czech reimbursement list for foods for special medical purposes from 1 November 2026

🇨🇿 SÚKL · Fri 23 Oct 2026

The Czech medicines authority has issued the November edition of its list of prices and reimbursements for foods for special medical purposes, reflecting 12% VAT and the current ministerial price decision.

The State Institute for Drug Control (SÚKL) published on 23 October 2026 its list of prices and reimbursements for foods for special medical purposes (PZLÚ), effective 1 November 2026. The list is issued under Section 39zb(1) of Act No. 48/1997 on public health insurance and was released by the institute's price and reimbursement regulation section.

According to SÚKL, the list is issued on the first day of each calendar month. It sets out all categorised and non-categorised PZLÚ reimbursed from public health insurance. For categorised products it gives the manufacturer's notified prices, and for non-categorised products the maximum manufacturer prices set by the authority. It also states the amount and conditions of reimbursement, the highest possible reimbursement for the end consumer, and the co-payment that counts towards the patient limit. For categorised products it also lists the basic reimbursement amounts for each reimbursement group.

The list takes account of 12% VAT and of Ministry of Health Price Decision No. 1/2026/OLZP of 24 October 2025, which regulates prices of medicinal products and PZLÚ.

SÚKL has released the data in XLS and CSV formats. These include the full file of current reimbursements (SCAU261101v02_PZLU) and files showing additions and removals against the previous list, SCAU261001v02_PZLU. Separate spreadsheets cover changes in reimbursements, maximum prices, countable co-payments and indication restrictions. Supporting code lists and a data interface specification are also available. The source text does not detail the individual changes.

What it means for your team

  • Market-access and pricing teams with PZLÚ on the Czech market should compare the November files against the October list to identify changes affecting their products.
  • Reimbursement changes and indication restriction updates are published in separate spreadsheets, so both sets should be checked.
  • The list is based on 12% VAT and Price Decision No. 1/2026/OLZP, which should be reflected in any price modelling.
  • The item concerns pricing and reimbursement only and carries no direct pharmacovigilance or safety implications.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →